Understanding these mutations not only aids in risk stratification but also informs targeted therapy approaches, such as FLT3 inhibitors for FLT3-ITD-positive AML or intensive chemotherapy regimens for NPM1-mutated AML [7,8]. This evidence concerns the gene FLT3 and acute myeloid leukemia.